Clinicians Show Modest Response To Elevated Lipoprotein Levels In Low-risk Patients

Elevated Lipoprotein(a) [Lp(a)] is an independent, genetically wished consequence facet for atherosclerotic cardiovascular illness (ASCVD), pinch levels >50 mg/dL affecting 20–30% of nan world population. Despite therapeutic limitations, liking successful Lp(a) has increased, driven by its prognostic worth and nan emergence of targeted therapies. However, pinch expanding guideline-directed Lp(a) testing, clinician consequence to elevated concentrations, particularly successful nan absence of guideline-based curen indications, remains unclear.

In a caller study and position astatine nan American College of Cardiology, researchers recovered that elevated Lp(a) was associated pinch earlier and much predominant initiation of preventive pharmacotherapy. These consequence rates were humble successful a low-risk, superior prevention study population.

Specifically, astir 80% of patients pinch elevated Lp(a) >50 mg/dL did not initiate lipid-lowering therapy successful nan absence of different ASCVD consequence factors. Drugs that drastically little "bad" LDL cholesterin (PCSK9 inhibitors) and aspirin initiation was moreover little common, suggesting selective alternatively than systematic responses to elevated Lp(a). Together, these findings propose that elevated Lp(a) appears to only occasionally power prescribing behaviour – behaviour accordant pinch erstwhile reports.

While not presently a modular denotation for statin therapy alone, elevated Lp(a) is progressively utilized by clinicians arsenic a "risk enhancer" to guideline much aggressive, albeit often unstandardized, preventive measures."

Sheilah A. Bernard MD, corresponding author, subordinate professor of medicine, Boston University Chobanian & Avedisian School of Medicine

The researchers conducted a multicenter retrospective observational cohort study evaluating initiation of preventive pharmacotherapy pursuing Lp(a) measurement among astir 15,000 patients astatine debased consequence for ASCVD. Within 90 days of Lp(a) measurement, lipid-lowering therapy initiation was uncommon but much predominant among patients pinch elevated Lp(a) compared to those pinch non-elevated Lp(a). PCSK9 inhibitor initiation was uncommon but much predominant among patients pinch elevated Lp(a). Similarly, aspirin initiation was uncommon but much predominant among patients pinch elevated Lp(a).

According to nan researchers, these findings should not beryllium interpreted arsenic indicating that specified prescribing is guideline-directed. "Current recommendations admit Lp(a) arsenic a risk-enhancing facet alternatively than arsenic a curen target, and nary therapy is approved solely for Lp(a) elevation. Our study describes modern believe alternatively than due management," adds Bernard who besides is simply a cardiologist astatine Boston Medical Center.

The findings besides look online successful nan American Journal of Preventive Cardiology.